The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (“the Company”) on 4 May 20022. The Annual General Meeting was carried out through advance voting (postal voting) only.
Full PDFPeter Nordkild, CEO: “Despite the challenges of the last year we remain committed to our goal of providing new effective therapy to patients with various neurological disorders. Topline data for our phase IIa study in Tourette are still expected in Q1 of 2023 and the study remains fully funded. We maintain our full focus on…
Full PDFNOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. The shareholders of Asarina Pharma AB (publ) reg. no. 556698-0750 (the “Company”) are hereby given notice of the Annual General Meeting (the “AGM”) to be held on 4 May 2022.
Full PDFPeter Nordkild, CEO: “We enter the new financial year with renewed energy and optimism after Region Hovedstaden finally signed the required papers for our clinical test sites in Copenhagen, and we achieved ‘First Patient First Visit’ on 16 February in our phase IIa clinical study in Tourette syndrome. We are now moving ahead confidently in…
Full PDF(Stockholm, 16 February, 2022.) Asarina Pharma announces today that ‘First Patient First Visit’ has taken place in its phase IIa clinical study in Tourette syndrome at Bispebjerg University Hospital, Copenhagen. The Asarina compound being trialled, Sepranolone, is an endogenous neurosteroid that has already demonstrated a strong safety profile in previous clinical studies. In preclinical studies…
Full PDF